表皮生长因子受体拮抗剂相关皮肤不良反应表现及治疗进展

发布时间：2018-07-24 10:14

【摘要】：近十几年来,除了手术、化疗、放疗三项常规治疗手段之外,分子靶向药物使肿瘤治疗有了重大突破。分子靶向药物治疗作为一种新型治疗手段,正在肿瘤内科治疗领域发挥越来越重要的作用。其中,表皮生长因子受体拮抗剂(epidermal growth factor receptor inhibitors,EGFRIs)是目前临床应用最为广泛的一类分子靶向药物。EGFRIs的主要不良反应为皮肤不良反应、腹泻、乏力、间质性肺炎等。皮肤不良反应是EGFRIs最常见的不良反应,经常会影响患者生存质量,导致药物减量或停药。其主要表现为痤疮样皮疹甚至脓疱样丘疹、皮肤瘙痒、皮肤干燥、甲沟炎及甲裂、毛发改变及超敏反应。目前,临床上标准治疗方案包括抗生素、糖皮质激素、抗组胺药等,但是疗效并不满意。本文旨在对EGFRIs相关皮肤不良反应表现及治疗进展进行综述,以期为临床提供参考。
[Abstract]:In recent years, in addition to surgery, chemotherapy and radiotherapy, molecular targeted drugs have made a major breakthrough in tumor treatment. As a new therapeutic method, molecular targeted drug therapy is playing a more and more important role in the field of oncology. Among them, epidermal growth factor receptor antagonist (epidermal growth factor receptor inhibitors (EGFRIs) is one of the most widely used molecular targeting drugs. The main adverse reactions of EGFRIs are skin adverse reactions, diarrhea, fatigue, interstitial pneumonia and so on. Skin adverse reactions are the most common adverse reactions in EGFRIs, which often affect the quality of life of patients and lead to drug reduction or withdrawal. Its main manifestations are acne like rash and even pustular papules, pruritus, dry skin, thyroiditis and nail cleavage, hair change and hypersensitivity. At present, the standard therapy includes antibiotics, glucocorticoids and antihistamines, but the effect is not satisfactory. The purpose of this article is to review the clinical manifestation and treatment progress of EGFRIs related skin adverse reactions in order to provide reference for clinical practice.
【作者单位】：北京中医药大学中日友好临床医学院;中日友好医院中西医结合肿瘤科;
【基金】：北京市科委首都特色应用研究项目(编号:Z151100004015168)资助~~
【分类号】：R730.5

【参考文献】